This site is intended for healthcare professionals

European Commission approval for Isturisa for the treatment of people with endogenous Cushing’s syndrome.- Recordati

Read time: 1 mins
Published:19th Jan 2020
Recodati‘s inhibitor of cortisol synthesis, Isturisa (osilodrostat), has been approved by the European Commission (EC) for the treatment of people with endogenous Cushing’s syndrome, the company announced. The decision follows a European Medicines Agency (EMA) committee recommendation in November to approve Isturisa for that purpose. The therapy will be available in three dosages: 1 milligram (mg), 5 mg, and 10 mg film-coated tablets. Isturisa is an oral treatment that inhibits an enzyme called 11-beta-hydroxylase, which is involved in cortisol synthesis. Blocking the enzyme prevents excessive cortisol production, which normalizes the hormone’s levels in the body, reducing Cushing’s disease symptoms. Comment; Recordati acquired the global rights to two of Novartis’ medicines, Signifor and osilodrostat ( now Isturisa), for the treatment of patients suffering from endocrine diseases in July 2019..
Condition: Cushing's Syndrome
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.